NXTM News Alert Nxstage Medical (NXTM) 17.56 02/14/2015 09:3

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 10:37 AM

Nxstage Medical (NXTM) 17.56 $NXTM

Medtronic's Pipeline Flex Embolization Device Gets FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:05PM CST
Medtronic announced the FDA approval for its Pipeline Flex embolization device (the next-generation flow diversion device).
ICUI: 88.98 (+0.42), NXTM: 17.56 (-0.05), MDT: 75.26 (+0.33), ABAX: 60.93 (+0.65)

Uptrend Call Working As NxStage Medical Stock Rises 24.1% (NXTM)
Comtex SmarTrend(R) - Wed Feb 04, 11:13AM CST
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on October 22nd, 2014 at $14.37. In approximately 4 months, NxStage Medical has returned 24.12% as of today's recent price of $17.83.
NXTM: 17.56 (-0.05)

NxStage Hosts Panel Discussion on Home Nocturnal Hemodialysis at 2015 Annual Dialysis Conference
PR Newswire - Mon Feb 02, 7:00AM CST
NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of dialysis products, will host an educational panel discussion today on home nocturnal hemodialysis therapy ("nocturnal"

during the Annual Dialysis Conference (ADC) in New Orleans. A panel moderator will lead a discussion for dialysis providers on the NxStage System One(TM)'s recent U.S. Food and Drug Administration's (FDA) clearance for nocturnal therapy, and its significant and wide-reaching clinical and lifestyle benefits. Panelists will highlight their applications of best demonstrated practices, offer insight on applying these tactics to build and develop nocturnal programs and expand access to this important therapy option for patients. Featured panelists are Dr. Robert Lockridge of Lynchburg Nephrology Physicians, Dr. Christopher Hoy of DCI Rubin Dialysis, and Lisa Koester, CNN-NP Renal Nurse Practitioner of Washington University School of Medicine, Renal Division.
NXTM: 17.56 (-0.05)

Abaxis (ABAX) Beats Q3 Earnings, Revenues; Margin Grows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 12:50PM CST
Based on an encouraging top line, Abaxis' (ABAX) fiscal third-quarter gross profit rose 51% to $29.2 million
ICUI: 88.98 (+0.42), NXTM: 17.56 (-0.05), ABAX: 60.93 (+0.65), HSIC: 143.18 (+0.72)

Baxter (BAX) Beats Q4 Earnings Estimates, Sales Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 4:20PM CST
Baxter International Inc (BAX) reported fourth-quarter 2014 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 3 cents.
ICUI: 88.98 (+0.42), NXTM: 17.56 (-0.05), BAX: 70.39 (+0.31), NKTR: 13.54 (-0.14)

Mead Johnson's US Expansion Drives Q4 Earnings Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 10:09AM CST
Mead Johnson (MJN) achieved positive sales growth in two of its three segments, while sales growth in Asia was not up to the mark owing to Mead Johnson's weak performance in China.
ICUI: 88.98 (+0.42), NXTM: 17.56 (-0.05), MJN: 101.89 (+2.32), PAHC: 30.85 (+0.36)

St. Jude Q4 Earnings Meet Estimates on Modest Sales Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 11:30AM CST
St. Jude Medical Inc (STJ) reported adjusted EPS of $1.03, which was in line with the Zacks Consensus Estimate.
ICUI: 88.98 (+0.42), NXTM: 17.56 (-0.05), PAHC: 30.85 (+0.36), STJ: 67.48 (+0.65)

Shares of NXTM Up 32.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Jan 28, 9:51AM CST
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on October 22nd, 2014 at $14.37. In approximately 3 months, NxStage Medical has returned 31.99% as of today's recent price of $18.96.
NXTM: 17.56 (-0.05)

Stryker Lags Q4 Earnings, Revenue Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 7:21AM CST
Stryker Corp (SYK) reported disappointing fourth-quarter 2014 financial numbers.
ICUI: 88.98 (+0.42), SNN: 35.82 (-0.28), NXTM: 17.56 (-0.05), SYK: 94.51 (+1.14)

NxStage® to Report Fourth Quarter and Full Year 2014 Financial Results
PR Newswire - Wed Jan 28, 7:00AM CST
NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2014, on Thursday, February 26, 2015, before the opening of the financial markets.
NXTM: 17.56 (-0.05)

29.9% Return Seen to Date on SmarTrend NxStage Medical Call (NXTM)
Comtex SmarTrend(R) - Wed Jan 21, 9:16AM CST
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on October 22nd, 2014 at $14.37. In approximately 3 months, NxStage Medical has returned 29.90% as of today's recent price of $18.66.
NXTM: 17.56 (-0.05)

NxStage Establishes Annual Zenith Award To Recognize Excellence in Acute Renal Care
PR Newswire - Tue Jan 20, 7:00AM CST
NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced the creation of its annual Zenith Award to recognize acute renal care teams for their outstanding contributions to patient care. The award recipient will be announced on April 15, 2015 at a NxStage sponsored event during the 2015 AACN National Teaching Institute Critical Care Exposition in San Diego, California.
NXTM: 17.56 (-0.05)

Insider Trading Alert - FSL, NXTM And STAG Traded By Insiders
at The Street - Thu Jan 15, 9:06AM CST
Stocks with insider trader activity include FSL, NXTM and STAG
STAG: 25.49 (-0.11), NXTM: 17.56 (-0.05), FSL: 37.53 (+2.83)

NxStage Revises Up 2014 Guidance on Strong Home Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 4:15PM CST
NxStage Medical Inc. (NXTM) revised its fourth quarter and full year 2014 guidance.
NXTM: 17.56 (-0.05), BAX: 70.39 (+0.31), FMS: 36.43 (-0.65), RMTI: 11.17 (+0.15)

NxStage Medical increases 2014 guidance
Seeking Alpha - at Seeking Alpha - Tue Jan 13, 8:38AM CST

NXTM: 17.56 (-0.05)

NxStage Increases Revenue Guidance for the Fourth Quarter and Full-Year 2014
PR Newswire - Tue Jan 13, 7:00AM CST
NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today increased its revenue guidance for the fourth quarter and fiscal year ended December 31, 2014.
NXTM: 17.56 (-0.05)

Shares of NXTM Up 20.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Jan 06, 11:14AM CST
SmarTrend identified an Uptrend for NxStage Medical (NASDAQ:NXTM) on October 22nd, 2014 at $14.37. In approximately 3 months, NxStage Medical has returned 20.36% as of today's recent price of $17.29.
NXTM: 17.56 (-0.05)

Update: NxStage Bagged FDA Clearance For System One For Nocturnal Hemodialysis
Andy Batts - at Seeking Alpha - Thu Dec 25, 11:09AM CST

NXTM: 17.56 (-0.05)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Truck Drivers USA & Career Driver Unveil New Driver Agent

Revolutionizing Driver-Carrier Connections In today's cranking transportation scene, Truck Drivers USA (TDUSA) and Career Driver have taken a bold step to change up the driver recruitment game. They've launched what's being labeled as the first 'driver agent' within the Career Driver mobile app. It's the talk of the town in Sherwood, Arkansas, these days. This isn't just...

FCS Drives Key FDA Approvals in Cancer Treatment

Florida Cancer Specialists: Changing the Cancer Treatment Game Some organizations toot their horns, but every now and then, a group truly shakes up the playing field. Take Florida Cancer Specialists & Research Institute (FCS), for instance. Over years of relentless research, FCS has nailed its role in securing two significant FDA approvals aimed at expanding treatment...

Marshall Goldman Expands Footprint with Marino Acquisition

Revving Up in Florida: Marshall Goldman's Strategic Leap If you're tuned into the luxury car scene, you probably already heard Marshall Goldman is making moves into Florida. Buying Marino Performance Motors of West Palm Beach isn't just another notch on their belt—it's a strategic leap into their second-largest market. This ain't merely about showroom floor space. Think...

Gourmia Introduces Ceramic-Coated Air Fryer at Costco

A New Era for Home Cooking with Gourmia Stepping into the kitchen appliances arena with a dash of innovation, Gourmia has launched its first ceramic-coated air fryer, and it’s weaving its way exclusively onto the shelves of Costco. Now, it’s not just about frying anymore; it’s about adding style, efficiency, and a touch of healthy living to your countertop. But much...

Tessa AI: Revolutionizing Biomedical Research with AI

Shaking Up Research Evaluation When Siensmetrica decided it was high time for a name change, morphing into Tessa AI wasn't just a cosmetic shift. It was a nod to what stakeholders were already calling it and laid the ground for a broader mission statement. They're not sitting on their hands; they're crafting tools that tackle the scientific life cycle from start to...

AI-Powered Travel Transformation in Norway Revealed

AI-Driven Travel Meets Norway's Authentic Charm Well, folks, once again we're staring down the barrel of technology going full throttle in the travel game. Mindtrip, the savvy AI-powered travel platform, just inked a deal with the Norwegian Travel Cluster. It's their first tango in Europe, and they're not dipping their toes—they're diving headfirst into the icy fjords....

Cogent Communications' Q3 2026 Earnings Call Details

Cue the Countdown: Cogent’s Earnings Call Looms Another quarter rolls by, and with it comes Cogent Communications' chance to strut—or stumble—before the crowd. Their third-quarter earnings call on November 5, 2026, is like the opening bell for a stock that's zipped through more ups and downs than a tired bullfighter's routine. What the call reveals on that crisp...

xFusion Tackles Cooling and Power at OCP 2026

Bracing for an AI Revolution Ah, the world of AI — it's like the wild west out there, with data centers struggling to keep up as workloads skyrocket. Enter xFusion, a veteran in the computing infrastructure game, rolling out some seriously impressive tech at the 2026 Open Compute Project (OCP) Global Summit. The company's latest offering showcases how they're tackling...

Vayo Debuts as Booking Holdings Eyes $100M Investment

A travel revolution might just be on the horizon, courtesy of Booking Holdings' latest venture, Vayo. And they’re talking about throwing $100 million into it—subject to a few conditions, sure—but that’s not pocket change you toss around without a serious plan. Transforming Travel into a Seamless Experience Vayo’s got one job: making your travels less like a...

Omega Point's MCP Secures Anthropic Verification

In a world where investment decisions ride on razor-thin margins, Omega Point's MCP gains top-tier verification. Anthropic's seal of approval is stamped firmly on it, signalling to the wise investors out there that this engine ain't smoking mirrors. Since May, this player has been doing the rounds, but now, with Anthropic’s verification, it’s like Omega Point just...